Intellia Therapeutics (NTLA) Cash & Equivalents (2016 - 2025)
Historic Cash & Equivalents for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $193.4 million.
- Intellia Therapeutics' Cash & Equivalents rose 6049.55% to $193.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $193.4 million, marking a year-over-year increase of 6049.55%. This contributed to the annual value of $189.2 million for FY2024, which is 1656.73% down from last year.
- As of Q3 2025, Intellia Therapeutics' Cash & Equivalents stood at $193.4 million, which was up 6049.55% from $156.2 million recorded in Q2 2025.
- In the past 5 years, Intellia Therapeutics' Cash & Equivalents registered a high of $523.5 million during Q4 2022, and its lowest value of $120.5 million during Q3 2024.
- Its 5-year average for Cash & Equivalents is $190.9 million, with a median of $156.2 million in 2025.
- Per our database at Business Quant, Intellia Therapeutics' Cash & Equivalents crashed by 6409.08% in 2021 and then skyrocketed by 31718.28% in 2022.
- Intellia Therapeutics' Cash & Equivalents (Quarter) stood at $125.5 million in 2021, then soared by 317.18% to $523.5 million in 2022, then tumbled by 56.69% to $226.7 million in 2023, then decreased by 16.57% to $189.2 million in 2024, then rose by 2.22% to $193.4 million in 2025.
- Its Cash & Equivalents was $193.4 million in Q3 2025, compared to $156.2 million in Q2 2025 and $126.9 million in Q1 2025.